thioctic acid has been researched along with Diabetic Neuropathies in 151 studies
Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.
Diabetic Neuropathies: Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Time-dependent effects of alpha-lipoic acid/nifedipine/glimepiride combination on diabetic neuropathies were investigated in rats." | 8.12 | Diurnal efficacy of alpha-lipoic acid/nifedipine/glimepiride combination mitigates diabetic neuropathies in rats. ( Anafi, SB; Bisalla, M; Olurishe, TO; Oraebosi, MI, 2022) |
| "Time-dependent effects of alpha-lipoic acid/nifedipine/glimepiride combination on diabetic neuropathies were investigated in rats." | 4.12 | Diurnal efficacy of alpha-lipoic acid/nifedipine/glimepiride combination mitigates diabetic neuropathies in rats. ( Anafi, SB; Bisalla, M; Olurishe, TO; Oraebosi, MI, 2022) |
| "Its efficacy in neuropathic pain in diabetes mellitus still lacks enough research." | 3.11 | The 8-Week Efficacy of Frequency Rhythmic Electrical Modulated System (FREMS) as an Add-on Therapy in the Treatment of Symptomatic Diabetic Peripheral Polyneuropathy. ( Dziemidok, P; Gorczyca-Siudak, D, 2022) |
| " Our meta-analysis is aimed at evaluating the effects of oral-administered ALA versus a placebo in patients with DSPN and determining the optimal dosage for this treatment." | 3.01 | Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review. ( Chen, C; Hsieh, RY; Huang, IC; Sung, JY, 2023) |
| "Neuropathic pain is the most prevalent form of chronic pain caused by a disease of the nervous system, such as diabetic polyneuropathy." | 2.82 | Evaluation of the analgesic effect of ɑ-lipoic acid in treating pain disorders: A systematic review and meta-analysis of randomized controlled trials. ( Cassanego, G; De Freitas Bauermann, L; Rodrigues, P; Trevisan, G, 2022) |
| "To evaluate the effect of alpha-lipoic acid (LA) combined with transient intensive insulin therapy on adipokine level in patients with type 2 diabetic perineuropathy (DPN)." | 2.78 | [Effect of alpha-lipoic acid combined with transient intensive insulin therapy on adipokine level in patients with type 2 diabetic perineuropathy]. ( Song, MQ; Yang, L; Zang, SF, 2013) |
| " The rates of serious adverse events were higher on ALA (38." | 2.76 | Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. ( Boulton, AJ; Dyck, PJ; Freeman, R; Litchy, WJ; Low, PA; Maus, J; Munzel, U; Samigullin, R; Schütte, K; Tritschler, H; Vinik, AI; Ziegler, D, 2011) |
| " The incidence rates of adverse effects were 25." | 2.75 | [Efficacy and safety of high-dose α-lipoic acid in the treatment of diabetic polyneuropathy]. ( Chen, L; Gu, XM; Li, H; Liu, C; Lu, ZQ; Ning, G; Tang, ZY; Wu, JC; Zhang, SS, 2010) |
| "46 patients with type 1 diabetes and different forms of autonomic neuropathy, of mean age 38." | 2.71 | Alpha-lipoic acid in the treatment of autonomic diabetic neuropathy (controlled, randomized, open-label study). ( Dakovska, L; Koev, D; Tankova, T, 2004) |
| "Diabetic polyneuropathy is a serious complication in patients with diabetes mellitus." | 2.69 | Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathy. ( Amini, P; Frommeyer, R; Haak, E; Haak, T; Kusterer, K; Tritschler, HJ; Usadel, KH, 2000) |
| "treatment with thioctic acid resulted in a distinct improvement of subjective complaints." | 2.65 | Efficacy of thioctic acid in the therapy of peripheral diabetic neuropathy. ( Sachse, G; Willms, B, 1980) |
| " Data suggests that ALA has a short half-life and bioavailability (about 30%) triggered by its hepatic degradation, reduced solubility as well as instability in the stomach." | 2.61 | Insights on the Use of α-Lipoic Acid for Therapeutic Purposes. ( Akram, M; Antika, G; Berkay Yılmaz, Y; Boyunegmez Tumer, T; Capanoglu, E; Cho, WC; Fawzi Mahomoodally, M; Lobine, D; Martins, N; Riaz, M; Salehi, B; Sharifi-Rad, J; Sharopov, F, 2019) |
| "Objective To compare the clinical effectiveness of lipoic acid combined with epalrestat versus lipoic acid in treating diabetic peripheral neuropathy(DPN)." | 2.55 | Lipoic Acid Combined with Epalrestat versus Lipoic Acid in Treating Diabetic Peripheral Neuropathy:A Meta-analysis. ( Lin, HX; Lu, YK; Wang, XT; Xu, SA, 2017) |
| " The outcomes measured were as follows: clinical efficacy, median motor nerve conduction velocity (MNCV), median sensory nerve conduction velocity (SNCV), peroneal MNCV, peroneal SNCV and adverse effects." | 2.53 | Efficacy and safety of prostaglandin E1 plus lipoic acid combination therapy versus monotherapy for patients with diabetic peripheral neuropathy. ( Jiang, DQ; Li, MX; Ma, YJ; Wang, Y, 2016) |
| " Indeed, phenomena such as reduced solubility, lack of gastric stability and hepatic degradation determine a bioavailability of around 30% and a short half-life of ALA." | 2.50 | (R)-α-lipoic acid oral liquid formulation: pharmacokinetic parameters and therapeutic efficacy. ( Brufani, M; Figliola, R, 2014) |
| "Based on the currently available evidence, when given intravenously at a dosage of 600 mg once daily over a period of three weeks, alpha lipoic acid leads to a significant and clinically relevant reduction in neuropathic pain (grade of recommendation A)." | 2.46 | Alpha lipoic acid: a new treatment for neuropathic pain in patients with diabetes? ( Alkhalaf, A; Bilo, HJ; Kleefstra, N; Mijnhout, GS, 2010) |
| "In patients with type 2 diabetes, recent studies have reported that intravenous (i." | 2.41 | Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. ( Evans, JL; Goldfine, ID, 2000) |
| "Metformin has beneficial pharmacological effects on the preservation of peripheral nerves in diabetic rats and its effects are comparable to those of ALA." | 1.56 | Metformin Preserves Peripheral Nerve Damage with Comparable Effects to Alpha Lipoic Acid in Streptozotocin/High-Fat Diet Induced Diabetic Rats. ( Jin, HY; Kim, SH; Park, TS, 2020) |
| "Alprostadil is a commonly used vasodilator, and alpha lipoic acid is an antioxidant, which can effectively reduce oxidative stress responses and delay the progression of diabetes mellitus and its complications." | 1.56 | The clinical effectiveness and safety of alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropathy: A protocol for systematic review and meta-analysis. ( Fang, C; Fang, X; Guan, H; Han, P; Li, L; Qiu, S; Ye, M; Zhang, L, 2020) |
| "Our study will provide evidence to assess whether epalrestat combined with ALA is an optional treatment for patients with DPN." | 1.48 | The clinical efficacy of epalrestat combined with α-lipoic acid in diabetic peripheral neuropathy: Protocol for a systematic review and meta-analysis. ( Jin, Y; Lin, H; Wang, X; Xu, S; Zhang, R, 2018) |
| " Dosage of the drug was 600 mg daily." | 1.39 | [Efficacy of thiolepta in diabetic polyneuropathy: results of the study ETIKA]. ( Fokina, AS; Golovacheva, VA; Kochetov, AG; Strokov, IA, 2013) |
| "Distal symmetric sensory-motor diabetic polyneuropathy (DPN)--the most common variant of diabetic neuropathy, which is expressed by more than 50% of patients with diabetes mellitus (DM) 1 and type 2." | 1.38 | [The clinic, diagnosis, complex treatment of diabetic polyneuropathy]. ( Terent'eva, NV, 2012) |
| "Thioctic acid treatment was discontinued 2 days after admission." | 1.37 | Thioctic acid-induced acute cholestatic hepatitis. ( Castiglioni, T; Ridruejo, E; Silva, MO, 2011) |
| "Diabetic neuropathies are a family of nerve disorders caused by diabetes." | 1.35 | Coenzyme Q(10) and alpha-lipoic acid supplementation in diabetic rats: conduction velocity distributions. ( Ayaz, M; Gokbel, H; Okudan, N; Tuncer, S, 2008) |
| " It has been shown that berlition in dosage 300 mg twice daily for 3 months exerts a significant positive effect on the state of sensory and motor functions as well as neurophysiologic disturbances." | 1.35 | [The use of dipyridamole (curantyl) in combination with alpha-lipoic acid in the treatment of diabetic neuropathy with retinopathy]. ( Al-Zamil, MKh, 2008) |
| "Substance P was depleted to 51% in the control rats (p < 0." | 1.31 | Oxidative stress participates in the breakdown of neuronal phenotype in experimental diabetic neuropathy. ( Corder, R; Hounsom, L; Patel, J; Tomlinson, DR, 2001) |
| "We included 43 patients with type 1 diabetes in this cross-sectional study." | 1.30 | Insufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. ( Bierhaus, A; Hofmann, MA; Joswig, M; Kanitz, M; Klevesath, MS; Lee, V; Morcos, M; Nawroth, PP; Schiekofer, S; Tritschler, H; Wahl, P; Ziegler, R, 1998) |
| "Patients with diabetic polyneuropathy are known to have an impaired neurovascular reflex arc compared to healthy controls." | 1.30 | The effect of alpha-lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy. ( Haak, ES; Haak, T; Kohleisen, M; Kusterer, K; Usadel, KH; Yilmaz, A, 1999) |
| "Treatment with thioctic acid did not alter the heart rate response to standing up or Valsalva manoeuvre of the diabetics with peripheral neuropathy." | 1.27 | [Diabetic autonomic neuropathy of the heart and its treatment with thioctic acid]. ( Heuer, LJ; Studt, J, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (6.62) | 18.7374 |
| 1990's | 21 (13.91) | 18.2507 |
| 2000's | 49 (32.45) | 29.6817 |
| 2010's | 50 (33.11) | 24.3611 |
| 2020's | 21 (13.91) | 2.80 |
| Authors | Studies |
|---|---|
| Esin, RG | 1 |
| Khairullin, IK | 1 |
| Esin, OR | 1 |
| Oraebosi, MI | 1 |
| Olurishe, TO | 1 |
| Anafi, SB | 1 |
| Bisalla, M | 1 |
| Cassanego, G | 1 |
| Rodrigues, P | 1 |
| De Freitas Bauermann, L | 1 |
| Trevisan, G | 1 |
| Lekhanya, PK | 1 |
| Mokgalaboni, K | 1 |
| Fasipe, B | 1 |
| Faria, A | 1 |
| Laher, I | 1 |
| Zhang, T | 1 |
| Zhang, D | 1 |
| Zhang, Z | 3 |
| Tian, J | 1 |
| An, J | 1 |
| Zhang, W | 1 |
| Ben, Y | 1 |
| Gorczyca-Siudak, D | 1 |
| Dziemidok, P | 1 |
| Capece, U | 1 |
| Moffa, S | 1 |
| Improta, I | 1 |
| Di Giuseppe, G | 1 |
| Nista, EC | 1 |
| Cefalo, CMA | 1 |
| Cinti, F | 1 |
| Pontecorvi, A | 1 |
| Gasbarrini, A | 1 |
| Giaccari, A | 1 |
| Mezza, T | 1 |
| Jermendy, G | 2 |
| Rokszin, G | 1 |
| Fábián, I | 1 |
| Kempler, P | 7 |
| Wittmann, I | 1 |
| Hsieh, RY | 1 |
| Huang, IC | 1 |
| Chen, C | 1 |
| Sung, JY | 1 |
| Salehi, B | 1 |
| Berkay Yılmaz, Y | 1 |
| Antika, G | 1 |
| Boyunegmez Tumer, T | 1 |
| Fawzi Mahomoodally, M | 1 |
| Lobine, D | 1 |
| Akram, M | 1 |
| Riaz, M | 1 |
| Capanoglu, E | 1 |
| Sharopov, F | 1 |
| Martins, N | 1 |
| Cho, WC | 1 |
| Sharifi-Rad, J | 1 |
| Won, JC | 1 |
| Kwon, HS | 1 |
| Moon, SS | 1 |
| Chun, SW | 1 |
| Kim, CH | 1 |
| Park, IB | 1 |
| Kim, IJ | 1 |
| Lee, J | 1 |
| Cha, BY | 1 |
| Park, TS | 6 |
| Srivastava, A | 1 |
| Gupta, V | 1 |
| Maheshwari, PK | 1 |
| Han, X | 1 |
| Gao, Y | 1 |
| Wang, S | 1 |
| Chen, Q | 1 |
| El-Nahas, MR | 1 |
| Elkannishy, G | 1 |
| Abdelhafez, H | 1 |
| Elkhamisy, ET | 1 |
| El-Sehrawy, AA | 1 |
| Kim, SH | 1 |
| Jin, HY | 4 |
| Yan, T | 1 |
| Li, D | 1 |
| Didangelos, T | 1 |
| Karlafti, E | 1 |
| Kotzakioulafi, E | 1 |
| Kontoninas, Z | 1 |
| Margaritidis, C | 1 |
| Giannoulaki, P | 1 |
| Kantartzis, K | 1 |
| Guan, H | 1 |
| Ye, M | 1 |
| Fang, C | 1 |
| Zhang, L | 1 |
| Han, P | 1 |
| Qiu, S | 1 |
| Fang, X | 1 |
| Li, L | 1 |
| Jeffrey, S | 1 |
| Samraj, PI | 1 |
| Raj, BS | 1 |
| Nádró, B | 1 |
| Lőrincz, H | 1 |
| Molnár, Á | 1 |
| Szentpéteri, A | 1 |
| Zöld, E | 1 |
| Seres, I | 1 |
| Páll, D | 1 |
| Paragh, G | 1 |
| Harangi, M | 1 |
| Sztanek, F | 1 |
| Davidson, EP | 3 |
| Coppey, LJ | 4 |
| Shevalye, H | 2 |
| Obrosov, A | 2 |
| Kardon, RH | 2 |
| Yorek, MA | 5 |
| Várkonyi, T | 2 |
| Körei, A | 1 |
| Putz, Z | 1 |
| Martos, T | 1 |
| Keresztes, K | 1 |
| Lengyel, C | 1 |
| Nyiraty, S | 1 |
| Stirban, A | 1 |
| Wang, XT | 1 |
| Lin, HX | 1 |
| Xu, SA | 1 |
| Lu, YK | 1 |
| Wang, X | 1 |
| Lin, H | 1 |
| Xu, S | 1 |
| Jin, Y | 1 |
| Zhang, R | 1 |
| Agathos, E | 1 |
| Tentolouris, A | 1 |
| Eleftheriadou, I | 1 |
| Katsaouni, P | 1 |
| Nemtzas, I | 1 |
| Petrou, A | 1 |
| Papanikolaou, C | 1 |
| Tentolouris, N | 1 |
| Lee, KA | 2 |
| Lee, NY | 1 |
| Mrakic-Sposta, S | 1 |
| Vezzoli, A | 1 |
| Maderna, L | 1 |
| Gregorini, F | 1 |
| Montorsi, M | 1 |
| Moretti, S | 1 |
| Greco, F | 1 |
| Cova, E | 1 |
| Gussoni, M | 1 |
| Jiang, DQ | 3 |
| Xu, LC | 1 |
| Jiang, LL | 1 |
| Li, MX | 3 |
| Wang, Y | 6 |
| Tasci, I | 1 |
| Demir, CF | 1 |
| Kuloglu, T | 1 |
| Sadeghiyan Galeshkalami, N | 1 |
| Abdollahi, M | 1 |
| Najafi, R | 1 |
| Baeeri, M | 1 |
| Jamshidzade, A | 1 |
| Falak, R | 1 |
| Davoodzadeh Gholami, M | 1 |
| Hassanzadeh, G | 1 |
| Mokhtari, T | 1 |
| Hassani, S | 1 |
| Rahimifard, M | 1 |
| Hosseini, A | 1 |
| Pieralice, S | 1 |
| Vari, R | 1 |
| Minutolo, A | 1 |
| Maurizi, AR | 1 |
| Fioriti, E | 1 |
| Napoli, N | 1 |
| Pozzilli, P | 1 |
| Manfrini, S | 1 |
| Maddaloni, E | 1 |
| Hassanien, M | 1 |
| Elawamy, A | 1 |
| Kamel, EZ | 1 |
| Khalifa, WA | 1 |
| Abolfadl, GM | 1 |
| Roushdy, ASI | 1 |
| El Zohne, RA | 1 |
| Makarem, YS | 1 |
| Xu, Q | 1 |
| Pan, J | 1 |
| Yu, J | 1 |
| Liu, X | 1 |
| Liu, L | 1 |
| Zuo, X | 1 |
| Wu, P | 1 |
| Deng, H | 1 |
| Zhang, J | 1 |
| Ji, A | 1 |
| Ibrahimpasic, K | 1 |
| Strokov, IA | 3 |
| Fokina, AS | 1 |
| Golovacheva, VA | 1 |
| Kochetov, AG | 1 |
| Yang, L | 1 |
| Zang, SF | 1 |
| Song, MQ | 1 |
| Zhivolupov, SA | 1 |
| Samartsev, IN | 1 |
| Rashidov, NA | 1 |
| Bodrova, TV | 1 |
| Vorob'eva, MN | 1 |
| Sergienko, VA | 1 |
| Segin, VB | 1 |
| Samir, A | 1 |
| Sergienko, AA | 1 |
| Wu, JZ | 1 |
| Baek, HS | 2 |
| He, F | 1 |
| Zhang, Y | 1 |
| Sun, L | 1 |
| He, S | 1 |
| Pan, YN | 1 |
| Zhang, ZY | 1 |
| Koufaki, M | 1 |
| Dominguez, JM | 1 |
| Grant, MB | 1 |
| Brufani, M | 1 |
| Figliola, R | 1 |
| Papanas, N | 2 |
| Ziegler, D | 14 |
| Dworacka, M | 1 |
| Iskakova, S | 1 |
| Krzyżagórska, E | 1 |
| Wesołowska, A | 1 |
| Kurmambayev, Y | 1 |
| Dworacki, G | 1 |
| Holmes, A | 1 |
| Garcia-Alcala, H | 1 |
| Santos Vichido, CI | 1 |
| Islas Macedo, S | 1 |
| Genestier-Tamborero, CN | 1 |
| Minutti-Palacios, M | 1 |
| Hirales Tamez, O | 1 |
| García, C | 1 |
| Low, PA | 8 |
| Freeman, R | 2 |
| Tritschler, H | 6 |
| Vinik, AI | 3 |
| Ma, YJ | 1 |
| Bartkoski, S | 1 |
| Day, M | 1 |
| Janíčková Žďárská, D | 1 |
| Kvapil, M | 1 |
| Seyit, DA | 1 |
| Degirmenci, E | 1 |
| Oguzhanoglu, A | 1 |
| Han, Y | 1 |
| Wang, M | 1 |
| Shen, J | 1 |
| Zhao, M | 1 |
| Huang, J | 1 |
| Chen, Y | 1 |
| Chen, Z | 1 |
| Hu, Y | 2 |
| Yorek, MS | 1 |
| Salinthone, S | 1 |
| Yadav, V | 1 |
| Bourdette, DN | 1 |
| Carr, DW | 1 |
| Becić, F | 1 |
| Kapić, E | 1 |
| Rakanović-Todić, M | 1 |
| Ayaz, M | 1 |
| Tuncer, S | 1 |
| Okudan, N | 1 |
| Gokbel, H | 1 |
| Al-Zamil, MKh | 1 |
| Tavakoli, M | 1 |
| Malik, RA | 1 |
| Singh, U | 1 |
| Jialal, I | 1 |
| Bureković, A | 1 |
| Terzić, M | 1 |
| Alajbegović, S | 1 |
| Vukojević, Z | 1 |
| Hadzić, N | 1 |
| Poh, ZX | 1 |
| Goh, KP | 1 |
| Shay, KP | 1 |
| Moreau, RF | 1 |
| Smith, EJ | 1 |
| Smith, AR | 2 |
| Hagen, TM | 2 |
| Munzel, U | 3 |
| Ghibu, S | 1 |
| Richard, C | 1 |
| Vergely, C | 1 |
| Zeller, M | 1 |
| Cottin, Y | 1 |
| Rochette, L | 1 |
| Skalská, S | 1 |
| Kucera, P | 1 |
| Goldenberg, Z | 1 |
| Stefek, M | 1 |
| Kyselová, Z | 1 |
| Jariabka, P | 1 |
| Gajdosíková, A | 1 |
| Klobucníková, K | 1 |
| Traubner, P | 1 |
| Stolc, S | 1 |
| Mijnhout, GS | 1 |
| Alkhalaf, A | 1 |
| Kleefstra, N | 1 |
| Bilo, HJ | 1 |
| Winkler, G | 1 |
| Kuritzky, L | 1 |
| Kanorskiĭ, SG | 1 |
| Kanorskaia, IuS | 1 |
| Gu, XM | 1 |
| Zhang, SS | 1 |
| Wu, JC | 1 |
| Tang, ZY | 1 |
| Lu, ZQ | 1 |
| Li, H | 1 |
| Liu, C | 1 |
| Chen, L | 1 |
| Ning, G | 1 |
| Ametov, AS | 3 |
| Novosadova, MV | 1 |
| Barinov, AN | 1 |
| Samigullin, R | 4 |
| Trischler, HJ | 1 |
| Ridruejo, E | 1 |
| Castiglioni, T | 1 |
| Silva, MO | 1 |
| Litchy, WJ | 2 |
| Boulton, AJ | 1 |
| Maus, J | 2 |
| Schütte, K | 3 |
| Dyck, PJ | 3 |
| Maltezos, E | 1 |
| Volchegorskiĭ, IA | 1 |
| Rassokhina, LM | 1 |
| Miroshnichenko, IIu | 1 |
| Han, T | 1 |
| Bai, J | 1 |
| Liu, W | 1 |
| Terent'eva, NV | 1 |
| Shotton, HR | 2 |
| Clarke, S | 1 |
| Lincoln, J | 2 |
| Barinov, A | 2 |
| Hermann, R | 1 |
| Kozlova, N | 1 |
| Nehrdich, D | 1 |
| Novosadova, M | 2 |
| O'Brien, PC | 1 |
| Reljanovic, M | 3 |
| Schuette, K | 2 |
| Strokov, I | 1 |
| Tritschler, HJ | 6 |
| Wessel, K | 1 |
| Yakhno, N | 2 |
| Meyer, FP | 1 |
| Gellett, JS | 1 |
| Honma, H | 1 |
| Podratz, JL | 1 |
| Windebank, AJ | 1 |
| SCHREIBER, FK | 1 |
| SLADKI, E | 1 |
| MALDYK, H | 1 |
| PRUSINSKI, A | 1 |
| NAKAO, K | 1 |
| KITO, S | 1 |
| TAKASU, T | 1 |
| TASAKA, S | 1 |
| Nowak, H | 1 |
| Vargha, P | 1 |
| Broadbent, S | 1 |
| Shenvi, SV | 1 |
| Widlansky, M | 1 |
| Suh, JH | 1 |
| Baydas, G | 1 |
| Donder, E | 1 |
| Kiliboz, M | 1 |
| Sonkaya, E | 1 |
| Tuzcu, M | 1 |
| Yasar, A | 1 |
| Nedzvetskii, VS | 1 |
| Bruckner, I | 1 |
| Bustan, C | 1 |
| Adamescu, E | 1 |
| Dobjanschi, C | 1 |
| Wepner, U | 1 |
| Vereşiu, IA | 1 |
| Tankova, T | 2 |
| Koev, D | 2 |
| Dakovska, L | 1 |
| Braune, S | 1 |
| Cherninkova, S | 1 |
| Naruse, K | 1 |
| Nakamura, J | 1 |
| Bregovskiĭ, VB | 1 |
| Posokhina, OV | 1 |
| Karpova, IA | 1 |
| Bansal, V | 1 |
| Kalita, J | 1 |
| Misra, UK | 1 |
| Medvedeva, LA | 1 |
| Gnezdilov, AV | 1 |
| Zagorul'ko, OI | 1 |
| Syrovegin, AV | 1 |
| Samoĭlova, NV | 1 |
| Slashchuk, IuI | 1 |
| Ametov, A | 1 |
| Gurieva, I | 1 |
| Raz, I | 1 |
| Pitel, S | 1 |
| Raccah, D | 1 |
| Gerbi, A | 1 |
| Pieroni, G | 1 |
| Vague, P | 1 |
| Coste, TC | 1 |
| Joung, SJ | 1 |
| Park, JH | 1 |
| Wernicke, JF | 1 |
| Wang, F | 1 |
| Pritchett, YL | 1 |
| Smith, TR | 1 |
| Raskin, J | 1 |
| D'Souza, DN | 1 |
| Iyengar, S | 1 |
| Chappell, AS | 1 |
| Láhoda, F | 1 |
| Studt, J | 1 |
| Heuer, LJ | 1 |
| Sachse, G | 1 |
| Willms, B | 1 |
| Nagamatsu, M | 1 |
| Nickander, KK | 3 |
| Schmelzer, JD | 2 |
| Raya, A | 1 |
| Wittrock, DA | 1 |
| Ou, P | 1 |
| Wolff, SP | 1 |
| Kähler, W | 1 |
| Kuklinski, B | 1 |
| Rühlmann, C | 1 |
| Plötz, C | 1 |
| Hanefeld, M | 2 |
| Ruhnau, KJ | 2 |
| Meissner, HP | 1 |
| Lobisch, M | 3 |
| Gries, FA | 4 |
| McPhee, BR | 1 |
| Schatz, H | 1 |
| Conrad, F | 1 |
| Ulrich, H | 1 |
| Reichel, G | 2 |
| Köbberling, J | 1 |
| Hompesch, M | 1 |
| Biewenga, G | 1 |
| Haenen, GR | 1 |
| Bast, A | 1 |
| Cameron, NE | 2 |
| Cotter, MA | 2 |
| Horrobin, DH | 1 |
| Hounsom, L | 2 |
| Horrobin, DF | 1 |
| Corder, R | 2 |
| Tomlinson, DR | 2 |
| Hofmann, MA | 1 |
| Schiekofer, S | 1 |
| Kanitz, M | 1 |
| Klevesath, MS | 1 |
| Joswig, M | 1 |
| Lee, V | 1 |
| Morcos, M | 1 |
| Ziegler, R | 1 |
| Wahl, P | 1 |
| Bierhaus, A | 1 |
| Nawroth, PP | 1 |
| Keegan, A | 1 |
| Haak, ES | 1 |
| Usadel, KH | 2 |
| Kohleisen, M | 1 |
| Yilmaz, A | 1 |
| Kusterer, K | 2 |
| Haak, T | 2 |
| Rathmann, W | 1 |
| Haastert, B | 1 |
| Giani, G | 1 |
| Kozlova, NA | 1 |
| Mozolevskiĭ, IuV | 1 |
| Miasoedov, SP | 1 |
| Iakhno, NN | 1 |
| Hasche, H | 1 |
| Kerum, G | 1 |
| Malessa, R | 1 |
| Rett, K | 1 |
| Möller, W | 1 |
| Mehnert, H | 2 |
| Kishi, Y | 1 |
| Yao, JK | 1 |
| Zollman, PJ | 1 |
| Stevens, MJ | 1 |
| Obrosova, I | 1 |
| Cao, X | 1 |
| Van Huysen, C | 1 |
| Greene, DA | 1 |
| Haak, E | 1 |
| Amini, P | 1 |
| Frommeyer, R | 1 |
| Stansberry, KB | 1 |
| Pittenger, GL | 1 |
| Hedding-Eckerich, M | 1 |
| Eckert, MW | 1 |
| Balabolkin, MI | 1 |
| Kreminskaia, VM | 1 |
| Manukhina, EB | 1 |
| Bakhtina, LY | 1 |
| Malyshev, IY | 1 |
| Zoloev, GK | 1 |
| Kazikhanova, SI | 1 |
| Patel, J | 1 |
| van Dam, PS | 1 |
| van Asbeck, BS | 1 |
| Van Oirschot, JF | 1 |
| Biessels, GJ | 1 |
| Hamers, FP | 1 |
| Marx, JJ | 1 |
| Evans, JL | 1 |
| Goldfine, ID | 1 |
| Packer, L | 1 |
| Kraemer, K | 1 |
| Rimbach, G | 1 |
| Bilska, A | 1 |
| Włodek, L | 1 |
| Klein, W | 2 |
| Jörg, J | 1 |
| Metz, F | 1 |
| Scharafinski, H | 1 |
| Sauer, H | 1 |
| Böninger, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Alpha-Lipoic Acid on the Clinical Outcome of Patients With Sepsis[NCT05808946] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2023-03-10 | Recruiting | ||
| Ozone Therapy in Clinical, Psychological and Neurophysiological Pain Alleviation in Patients With Diabetic Neuropathy[NCT05000463] | 60 participants (Anticipated) | Interventional | 2022-02-25 | Not yet recruiting | |||
| Treatment With Alpha-lipoic Acid Over 16 Weeks in Type 2 Diabetic Patients With Symptomatic Polyneuropathy Who Responded to Initial 4-week High-dose Loading[NCT02439879] | Phase 4 | 45 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Exploratory Study of Lipoic Acid Supplementation on Oxidative Stress, Inflammatory and Functional Markers in Asthmatic Patients: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial.[NCT01221350] | 55 participants (Actual) | Interventional | 2010-11-30 | Completed | |||
| Effects of the Supplementation of α-lipoic Acid (ALA), Magnesium, Vitamin B6 and Vitamin D to Women Presenting Risk Factor for Pre-term Birth[NCT03952533] | 122 participants (Actual) | Interventional | 2019-05-05 | Completed | |||
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| The Effect of Lipoic Acid Natural Supplement on Cystine Stone Formation[NCT02910531] | Phase 2 | 50 participants (Anticipated) | Interventional | 2017-06-19 | Active, not recruiting | ||
| Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) NATHAN1 A Randomized, Placebo-controlled, Double-blind Multi-centre Trial With 2 Parallel Groups[NCT00977483] | Phase 3 | 460 participants (Actual) | Interventional | 1998-05-31 | Completed | ||
| Dose Finding and Tolerability Study of Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Peripheral Neuropathy[NCT01313117] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-blind,Placebo-controlled Multicentre Trial With 4 Parallel Groups[NCT00328601] | Phase 3 | 170 participants | Interventional | 2005-02-28 | Completed | ||
| A Double-Blind, Randomized, Placebo-Controlled Trial To Evaluate The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes[NCT02915263] | Phase 2 | 13 participants (Actual) | Interventional | 2017-09-11 | Terminated (stopped due to Funding withdrawn in the midst of the COVID pandemic) | ||
| The Effect of Alpha Lipoic Acid on the Incidence and Severity of Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients[NCT05023863] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2021-09-01 | Not yet recruiting | ||
| A Multicenter, Interventional, Two-arm, Parallel-group, Randomized, Double-blinded, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy of Alpha-Lipoic Acid in the Treatment of Symptomatic Diabetic Polyneuropathy in Egypt[NCT05813496] | Phase 4 | 400 participants (Anticipated) | Interventional | 2022-10-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Total symptoms score is a summation of presence, severity, and duration of the four main positive neuropathic sensory symptoms: lancinating/stabbing pain, burning pain, paresthesia, and asleep numbness (NCT02439879)
Timeframe: 20 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Alpha Lipoic Acid Treatment | 2.5 |
| Alpha Lipoic Acid Withdrawal | 3.1 |
Proteins can become modified by a large number of reactions involving reactive oxygen species. Among these, carbonylation is an irreversible and unrepairable oxidative reaction. The main protein modifications originated from oxidative stress comprise direct oxidation of aminoacids with a thiol group, such as cysteine, oxidative glycation, and carbonylation. Oxidative protein carbonylation induce protein degradation in a nonspecific manner. Chemically, oxidative carbonylation preferentially occurs at proline, threonine, lysine, and arginine, presumably through a metal-catalyzed activation of hydrogen peroxide to a reactive intermediate. Carbonylation usually refers to a process that forms reactive ketones or aldehydes that can be reacted by 2,4-dinitrophenylhydrazine (DNPH) to form hydrazones. Direct oxidation of side chains of lysine, arginine, proline, and threonine residues, among other aminoacids, produces DNPH detectable protein products (NCT01221350)
Timeframe: Baseline
| Intervention | nmol/mg (Mean) |
|---|---|
| Lipoic Acid | 7.5 |
| Placebo | 10.12 |
Proteins can become modified by a large number of reactions involving reactive oxygen species. Among these, carbonylation is an irreversible and unrepairable oxidative reaction. The main protein modifications originated from oxidative stress comprise direct oxidation of aminoacids with a thiol group, such as cysteine, oxidative glycation, and carbonylation. Oxidative protein carbonylation induce protein degradation in a nonspecific manner. Chemically, oxidative carbonylation preferentially occurs at proline, threonine, lysine, and arginine, presumably through a metal-catalyzed activation of hydrogen peroxide to a reactive intermediate. Carbonylation usually refers to a process that forms reactive ketones or aldehydes that can be reacted by 2,4-dinitrophenylhydrazine (DNPH) to form hydrazones. Direct oxidation of side chains of lysine, arginine, proline, and threonine residues, among other aminoacids, produces DNPH detectable protein products. (NCT01221350)
Timeframe: 60 days
| Intervention | nmol/mg (Mean) |
|---|---|
| Lipoic Acid | 3.24 |
| Placebo | 4.21 |
Eosinophils, a prominent feature of asthma, are found in increased numbers in the circulation and sputum, usually in relation to the severity of asthma. (NCT01221350)
Timeframe: Baseline
| Intervention | Eosinophil percentage in sputum cells (Mean) |
|---|---|
| Lipoic Acid | 12.88 |
| Placebo | 6.10 |
Eosinophils, a prominent feature of asthma, are found in increased numbers in the circulation and sputum, usually in relation to the severity of asthma. (NCT01221350)
Timeframe: 60 days
| Intervention | Eosinophil percentage in sputum cells (Mean) |
|---|---|
| Lipoic Acid | 6.39 |
| Placebo | 5.68 |
Induced sputum of GSH and GSSG levels at baseline. The ratio GSH/GSSG is considered an index of antioxidant status and reductive -SH groups. GSH and GSSG were measured by a microplate fluorescent assay. (NCT01221350)
Timeframe: Baseline
| Intervention | ratio (Mean) |
|---|---|
| Lipoic Acid | 81.42 |
| Placebo | 35.77 |
Change in the induced sputum of antioxidant parameters GSH and GSSG levels after 60 days of treatment. The ratio GSH/GSSG is considered an index of antioxidant status and reductive -SH groups. GSH and GSSG were measured by a microplate fluorescent assay. (NCT01221350)
Timeframe: 60 days
| Intervention | ratio (Mean) |
|---|---|
| Lipoic Acid | 58.6 |
| Placebo | 37.5 |
Inflammatory IL-4 sputum levels after 60 days of treatment. Sputum induction is a semi-invasive technique used to detect and monitor airway inflammation. IL-4 is a Th2 cytokine that promote airway inflammation in asthma. IL-4 drives the production of IgE in B cells. IL-4 was measured by ELISA. (NCT01221350)
Timeframe: 60 days
| Intervention | pg/mL (Mean) |
|---|---|
| Lipoic Acid | 14.53 |
| Placebo | 23.19 |
Inflammatory IL-4 sputum levels after 60 days of treatment. Sputum induction is a semi-invasive technique used to detect and monitor airway inflammation. IL-4 is a Th2 cytokine that promote airway inflammation in asthma. IL-4 drives the production of immunoglobulin E (IgE) in B cells. IL-4 was measured by ELISA. (NCT01221350)
Timeframe: Baseline
| Intervention | pg/mL (Mean) |
|---|---|
| Lipoic Acid | 37.77 |
| Placebo | 39.90 |
Assessment of Quality of life scores with the ACT (Asthma Control Test). The ACT is a way to determine if the asthma symptoms are well controlled. The Asthma Control Test™ (ACT™) is a five question health survey used to measure asthma control in individuals 12 years of age and older. The survey measures the elements of asthma control as defined by the National Heart, Lung, and Blood Institute (NHLBI). ACT is an efficient, reliable, and valid method of measuring asthma control, with or without, lung functioning measures such as spirometry. Each item includes 5 response options corresponding to a 5-point Likert-type rating scale. In scoring the ACT survey, responses for each of the 5 items are summed to yield a score ranging from 5 (poor control of asthma) to 25 (complete control of asthma). (NCT01221350)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Lipoic Acid | 13.65 |
| Placebo | 14.46 |
Assessment of Quality of life scores with the ACT (Asthma Control Test). The ACT is a way to determine if the asthma symptoms are well controlled. The Asthma Control Test™ (ACT™) is a five question health survey used to measure asthma control in individuals 12 years of age and older. The survey measures the elements of asthma control as defined by the National Heart, Lung, and Blood Institute (NHLBI). ACT is an efficient, reliable, and valid method of measuring asthma control, with or without, lung functioning measures such as spirometry. Each item includes 5 response options corresponding to a 5-point Likert-type rating scale. In scoring the ACT survey, responses for each of the 5 items are summed to yield a score ranging from 5 (poor control of asthma) to 25 (complete control of asthma). (NCT01221350)
Timeframe: 60 days
| Intervention | units on a scale (Mean) |
|---|---|
| Lipoic Acid | 19.13 |
| Placebo | 17.71 |
"The Asthma Quality of Life Questionnaire (AQLQ) was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma.~There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). The activity domain contains 5 'patient-specific' questions. This allows patients to select 5 activities in which they are most limited and these activities will be assessed at each follow-up. Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains (http://www.qoltech.co.uk/aqlq.html)." (NCT01221350)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Lipoic Acid | 3.86 |
| Placebo | 3.72 |
"The Asthma Quality of Life Questionnaire (AQLQ) was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma.~There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). The activity domain contains 5 'patient-specific' questions. This allows patients to select 5 activities in which they are most limited and these activities will be assessed at each follow-up. Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains (http://www.qoltech.co.uk/aqlq.html)." (NCT01221350)
Timeframe: 60 days
| Intervention | units on a scale (Mean) |
|---|---|
| Lipoic Acid | 5.57 |
| Placebo | 5.10 |
Measurement of spirometric parameters at baseline: Forced expiratory flow (FEF) is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. (NCT01221350)
Timeframe: Baseline
| Intervention | Liters/sec (Mean) |
|---|---|
| Lipoic Acid | 4.89 |
| Placebo | 6.09 |
Measurement of spirometric FEF after 60 days of treatment: Forced expiratory flow (FEF) is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. (NCT01221350)
Timeframe: 60 days
| Intervention | Liters/sec (Mean) |
|---|---|
| Lipoic Acid | 5.47 |
| Placebo | 6.10 |
Measurement of spirometric predicted parameters at baseline: Forced expiratory volume in 1 second (FEV1), volume that has been exhaled at the end of the first second of forced expiration. (NCT01221350)
Timeframe: Baseline
| Intervention | Liters (Mean) |
|---|---|
| Lipoic Acid | 2.01 |
| Placebo | 2.37 |
Measurement of spirometric predicted parameters after 60 days of treatment. Forced expiratory volume in 1 second (FEV1), volume that has been exhaled at the end of the first second of forced expiration. (NCT01221350)
Timeframe: 60 days
| Intervention | Liters (Mean) |
|---|---|
| Lipoic Acid | 2.26 |
| Placebo | 2.35 |
Measurement of spirometric predicted parameters at baseline. Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration, measured in liters. (NCT01221350)
Timeframe: Baseline
| Intervention | Liters (Mean) |
|---|---|
| Lipoic Acid | 2.74 |
| Placebo | 3.07 |
Measurement of spirometric predicted parameters at the baseline and after 60 days of treatment: Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration, measured in liters. (NCT01221350)
Timeframe: 60 days
| Intervention | Liters (Mean) |
|---|---|
| Lipoic Acid | 2.82 |
| Placebo | 3.06 |
(NCT01313117)
Timeframe: 4 months
| Intervention | participants (Number) |
|---|---|
| Alpha Lipoic Acid | 9 |
Based on acceptable adverse event (AE) profile and continual reassessment method dose escalation. (NCT01313117)
Timeframe: 4 months
| Intervention | mg (Number) |
|---|---|
| Alpha Lipoic Acid | 500 |
(NCT01313117)
Timeframe: 4 months
| Intervention | participants (Number) |
|---|---|
| Alpha Lipoic Acid | 7 |
"The standardized autonomic nervous system testing evaluates the heart rate variability to paced breathing.~Heart rate variability is reported in beats per minutes. The outcome measure is the heart rate variability at the final visit (7 weeks after initial infusion) minus the heart rate variability of the baseline visit. A positive result indicates an increase in heart rate variability (a better outcome), a negative result indicates a decrease in heart rate variability (a worse outcome)." (NCT02915263)
Timeframe: 7 weeks after first infusion
| Intervention | beats/minute (Mean) |
|---|---|
| 0.9% Sodium Chloride | -2.1 |
| IGIV-C | -2.5 |
"The visual analog scale (VAS) of pain allows for quantification of neuropathic pain.~The VAS pain scale is a line with markings that range from 0 (no pain) to 10 (worse pain), with whole digit intervals (thus an 11 point scale).~This outcome measure is the VAS pain score at the final visit (7 weeks after first infusion) minus the VAS pain score at the baseline visit. A positive result indicates that pain increased over the course of the study (a worse outcome), a negative result indicates that pain improved over the course of the trial (a better outcome)." (NCT02915263)
Timeframe: 7 weeks after first infusion
| Intervention | units on a scale (Mean) |
|---|---|
| 0.9% Sodium Chloride | 1.1 |
| IGIV-C | 1.6 |
"Skin biopsies will be evaluated by measuring the Intra-epidermal nerve fiber density.~Nerve fiber density is measured in the number of nerve fibers per millimeter. This outcome measure is the nerve fiber density at the final visit (7 weeks after the initial infusion) minus the nerve fiber density from the baseline visit. A positive result indicates that nerve fiber density increased over the course of the study (a better outcome), a negative result indicates that nerve fiber density decreased over the course of the trial (a worse outcome)." (NCT02915263)
Timeframe: 7 weeks after first infusion
| Intervention | fibers/mm (Mean) |
|---|---|
| 0.9% Sodium Chloride | -0.6 |
| IGIV-C | -0.3 |
"The Utah Early Neuropathy Scale (UENS) was developed specifically to detect and quantify early small-fiber sensory neuropathy and to recognize modest changes in sensory severity and distribution.~The UENS scale ranges from 0 (no neuropathy) to 42 (severe small fiber neuropathy). The outcome measure is the UENS score from 7 weeks (final evaluation) minus the UENS score from the baseline visit. A positive value indicates that neuropathy worsened over the course of the trial (a worse outcome), a negative score indicates that neuropathy improved over the course of the trial (a better outcome)." (NCT02915263)
Timeframe: 7 weeks after first infusion.
| Intervention | units on a scale (Mean) |
|---|---|
| 0.9% Sodium Chloride | 1.5 |
| IGIV-C | 3.9 |
41 reviews available for thioctic acid and Diabetic Neuropathies
| Article | Year |
|---|---|
Evaluation of the analgesic effect of ɑ-lipoic acid in treating pain disorders: A systematic review and meta-analysis of randomized controlled trials.
Topics: Analgesics; Diabetic Neuropathies; Humans; Neuralgia; Randomized Controlled Trials as Topic; Thiocti | 2022 |
Potential for Novel Therapeutic Uses of Alpha Lipoic Acid.
Topics: Antioxidants; Diabetic Neuropathies; Humans; Inflammation; Oxidative Stress; Thioctic Acid | 2023 |
Alpha-Lipoic Acid and Glucose Metabolism: A Comprehensive Update on Biochemical and Therapeutic Features.
Topics: Antioxidants; Autoimmune Diseases; Diabetic Neuropathies; Female; Glucose; Humans; Insulin Resistanc | 2022 |
Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review.
Topics: Administration, Oral; Databases, Factual; Diabetes Mellitus; Diabetic Neuropathies; Humans; Lower Ex | 2023 |
Insights on the Use of α-Lipoic Acid for Therapeutic Purposes.
Topics: Animals; Antioxidants; Biological Availability; Central Nervous System Diseases; Diabetic Neuropathi | 2019 |
The Role of Alpha-lipoic Acid Supplementation in the Prevention of Diabetes Complications: A Comprehensive Review of Clinical Trials.
Topics: Antioxidants; Diabetes Complications; Diabetes Mellitus; Diabetic Neuropathies; Dietary Supplements; | 2021 |
Advances in the management of diabetic neuropathy.
Topics: Adjuvants, Immunologic; Amines; Anticonvulsants; Antidepressive Agents; Antioxidants; Cardiovascular | 2017 |
Lipoic Acid Combined with Epalrestat versus Lipoic Acid in Treating Diabetic Peripheral Neuropathy:A Meta-analysis.
Topics: Diabetic Neuropathies; Drug Therapy, Combination; Humans; Randomized Controlled Trials as Topic; Rho | 2017 |
Fasudil combined with methylcobalamin or lipoic acid can improve the nerve conduction velocity in patients with diabetic peripheral neuropathy: A meta-analysis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antioxidants; Calcium Channel Blockers; Diabetic Neur | 2018 |
Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy.
Topics: Diabetic Neuropathies; Drug Therapy, Combination; Humans; Peripheral Nervous System Diseases; Thioct | 2013 |
Therapeutic applications of lipoic acid: a patent review (2011 - 2014).
Topics: Animals; Biological Availability; Chemistry, Pharmaceutical; Diabetic Neuropathies; Dietary Suppleme | 2014 |
(R)-α-lipoic acid oral liquid formulation: pharmacokinetic parameters and therapeutic efficacy.
Topics: Administration, Oral; Animals; Antioxidants; Diabetic Neuropathies; Humans; Thioctic Acid; Treatment | 2014 |
Efficacy of α-lipoic acid in diabetic neuropathy.
Topics: Antioxidants; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Diabetic Neuropat | 2014 |
Effects of prostaglandin E1 plus methylcobalamin alone and in combination with lipoic acid on nerve conduction velocity in patients with diabetic peripheral neuropathy: A meta-analysis.
Topics: Alprostadil; Diabetic Neuropathies; Drug Therapy, Combination; Humans; Neural Conduction; Randomized | 2015 |
Efficacy and safety of prostaglandin E1 plus lipoic acid combination therapy versus monotherapy for patients with diabetic peripheral neuropathy.
Topics: Adult; Alprostadil; Diabetic Neuropathies; Drug Therapy, Combination; Female; Humans; Male; Randomiz | 2016 |
Lipoic acid: a novel therapeutic approach for multiple sclerosis and other chronic inflammatory diseases of the CNS.
Topics: Alzheimer Disease; Animals; Antioxidants; Central Nervous System Diseases; Diabetic Neuropathies; Hu | 2008 |
[Pharmacological significance of alpha lipoic acid in up to date treatment of diabetic neuropathy].
Topics: Antioxidants; Diabetic Neuropathies; Humans; Thioctic Acid; Vitamin B Complex | 2008 |
Management of painful diabetic neuropathy.
Topics: Antidepressive Agents; Diabetic Neuropathies; Humans; Pancreas Transplantation; Physical Therapy Mod | 2008 |
Alpha-lipoic acid supplementation and diabetes.
Topics: Aging; Animals; Antioxidants; Biological Availability; Diabetes Mellitus; Diabetic Neuropathies; Die | 2008 |
A current update on the use of alpha lipoic acid in the management of type 2 diabetes mellitus.
Topics: Antioxidants; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Neuropath | 2009 |
Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.
Topics: Animals; Diabetic Neuropathies; Dietary Supplements; Humans; Hypertension; Inflammation; Models, Bio | 2009 |
Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.
Topics: Animals; Diabetic Neuropathies; Dietary Supplements; Humans; Hypertension; Inflammation; Models, Bio | 2009 |
Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.
Topics: Animals; Diabetic Neuropathies; Dietary Supplements; Humans; Hypertension; Inflammation; Models, Bio | 2009 |
Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.
Topics: Animals; Diabetic Neuropathies; Dietary Supplements; Humans; Hypertension; Inflammation; Models, Bio | 2009 |
Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.
Topics: Animals; Diabetic Neuropathies; Dietary Supplements; Humans; Hypertension; Inflammation; Models, Bio | 2009 |
Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.
Topics: Animals; Diabetic Neuropathies; Dietary Supplements; Humans; Hypertension; Inflammation; Models, Bio | 2009 |
Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.
Topics: Animals; Diabetic Neuropathies; Dietary Supplements; Humans; Hypertension; Inflammation; Models, Bio | 2009 |
Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.
Topics: Animals; Diabetic Neuropathies; Dietary Supplements; Humans; Hypertension; Inflammation; Models, Bio | 2009 |
Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.
Topics: Animals; Diabetic Neuropathies; Dietary Supplements; Humans; Hypertension; Inflammation; Models, Bio | 2009 |
Painful diabetic neuropathy: advantage of novel drugs over old drugs?
Topics: Amitriptyline; Analgesics; Antioxidants; Antipruritics; Capsaicin; Chronic Disease; Diabetic Neuropa | 2009 |
Antioxidant properties of an endogenous thiol: Alpha-lipoic acid, useful in the prevention of cardiovascular diseases.
Topics: Animals; Antioxidants; Cardiovascular Diseases; Diabetic Neuropathies; Dietary Supplements; Endothel | 2009 |
Alpha lipoic acid: a new treatment for neuropathic pain in patients with diabetes?
Topics: Diabetic Neuropathies; Humans; Pain; Thioctic Acid; Vitamin B Complex | 2010 |
[Pathomechanism of diabetic neuropathy: background of the pathogenesis-oriented therapy].
Topics: Adjuvants, Immunologic; Antioxidants; Blood Vessels; Diabetic Neuropathies; Hexosamines; Humans; Oxi | 2010 |
A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy.
Topics: Adult; Aged; Antioxidants; Asian People; Diabetic Neuropathies; Humans; Middle Aged; Randomized Cont | 2012 |
Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis.
Topics: Antioxidants; Diabetic Neuropathies; Double-Blind Method; Female; Humans; Male; Middle Aged; Randomi | 2004 |
Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress.
Topics: Animals; Antioxidants; Chelation Therapy; Chronic Disease; Coenzymes; Diabetic Neuropathies; Free Ra | 2004 |
Treatment of diabetic polyneuropathy with alpha-lipoic acid is evidence based.
Topics: Antioxidants; Diabetic Neuropathies; Evidence-Based Medicine; Humans; Meta-Analysis as Topic; Random | 2004 |
[Evidence-based pharmacotherapy of neuropathic pain syndromes].
Topics: Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Antioxidants; Cyclohexanec | 2004 |
[Pathogenesis and progression of neuropathies in diabetic patients with endothelial dysfunction].
Topics: Aldehyde Reductase; Animals; Antioxidants; C-Peptide; Diabetes Mellitus; Diabetic Neuropathies; Dise | 2005 |
Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review.
Topics: Animals; Antioxidants; Diabetic Neuropathies; Humans; Thioctic Acid | 2004 |
Diabetic neuropathy.
Topics: Aldehyde Reductase; Antioxidants; Autonomic Nervous System Diseases; Chronic Disease; Diabetic Neuro | 2006 |
Diabetic neuropathy: new strategies for treatment.
Topics: Aldehyde Reductase; Amines; Analgesics; Anticonvulsants; Antidepressive Agents; Antioxidants; Cycloh | 2008 |
Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy.
Topics: Antioxidants; Diabetic Neuropathies; Diet Therapy; Forecasting; Humans; Oxidation-Reduction; Thiocti | 1997 |
The role of lipoic acid in the treatment of diabetic polyneuropathy.
Topics: Aldehydes; Animals; Blood Glucose; Diabetic Neuropathies; Gluconeogenesis; Glucose; Humans; Hypergly | 1997 |
Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials.
Topics: Clinical Trials as Topic; Diabetic Neuropathies; Germany; Humans; Polyneuropathies; Protein Isoforms | 1999 |
Diabetic neuropathies.
Topics: Aldehyde Reductase; Animals; Diabetic Neuropathies; Enzyme Inhibitors; gamma-Linolenic Acid; Guanidi | 2000 |
Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes.
Topics: Administration, Oral; Antioxidants; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; | 2000 |
Molecular aspects of lipoic acid in the prevention of diabetes complications.
Topics: Antioxidants; Biological Availability; Cataract; Diabetes Complications; Diabetes Mellitus; Diabetic | 2001 |
[Biologic properties of lipoic acid].
Topics: Acquired Immunodeficiency Syndrome; Aging; Animals; Antioxidants; Cataract; Decarboxylation; Diabeti | 2002 |
31 trials available for thioctic acid and Diabetic Neuropathies
| Article | Year |
|---|---|
The 8-Week Efficacy of Frequency Rhythmic Electrical Modulated System (FREMS) as an Add-on Therapy in the Treatment of Symptomatic Diabetic Peripheral Polyneuropathy.
Topics: Diabetes Mellitus; Diabetic Neuropathies; Humans; Neuralgia; Polyneuropathies; Quality of Life; Sing | 2022 |
γ-Linolenic Acid versus α-Lipoic Acid for Treating Painful Diabetic Neuropathy in Adults: A 12-Week, Double-Placebo, Randomized, Noninferiority Trial.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; gamma-Linolenic Acid; Humans; Male; | 2020 |
Effect of electroacupuncture on diabetic neurogenic bladder: A randomized controlled trial protocol.
Topics: Adolescent; Adult; Aged; Diabetic Neuropathies; Electroacupuncture; Female; Humans; Male; Middle Age | 2020 |
Oral Alpha Lipoic Acid Treatment for Symptomatic Diabetic Peripheral Neuropathy: A Randomized Double-Blinded Placebo-Controlled Study.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Female; | 2020 |
Efficacy and Safety of the Combination of Superoxide Dismutase, Alpha Lipoic Acid, Vitamin B12, and Carnitine for 12 Months in Patients with Diabetic Neuropathy.
Topics: Aged; Carnitine; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Drug Combina | 2020 |
Effect of α-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy.
Topics: Adult; Aged; Demography; Diabetic Neuropathies; Disability Evaluation; Female; Humans; Male; Neuralg | 2018 |
Perineural Platelet-Rich Plasma for Diabetic Neuropathic Pain, Could It Make a Difference?
Topics: Adult; Analgesics; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Glycemic Control; Human | 2020 |
Alpha lipoic acid and glycaemic control in diabetic neuropathies at type 2 diabetes treatment.
Topics: Antioxidants; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Glycated Hemo | 2013 |
[Effect of alpha-lipoic acid combined with transient intensive insulin therapy on adipokine level in patients with type 2 diabetic perineuropathy].
Topics: Adiponectin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; H | 2013 |
[Metabolic therapy in neurology].
Topics: Acid-Base Equilibrium; Adult; Aged; Antioxidants; Diabetic Neuropathies; Female; Follow-Up Studies; | 2013 |
Treatment with α-Lipoic Acid over 16 Weeks in Type 2 Diabetic Patients with Symptomatic Polyneuropathy Who Responded to Initial 4-Week High-Dose Loading.
Topics: Administration, Oral; Adolescent; Adult; Analgesics; Antioxidants; Diabetes Mellitus, Type 2; Diabet | 2015 |
Predictors of improvement and progression of diabetic polyneuropathy following treatment with α-lipoic acid for 4 years in the NATHAN 1 trial.
Topics: Antioxidants; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Progression; Female; Follow- | 2016 |
Differential efficacy of methylcobalamin and alpha-lipoic acid treatment on symptoms of diabetic peripheral neuropathy.
Topics: Aged; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Humans; Male; Middle A | 2018 |
[Efficacy and safety of high-dose α-lipoic acid in the treatment of diabetic polyneuropathy].
Topics: Aged; Antioxidants; Diabetic Neuropathies; Double-Blind Method; Female; Humans; Male; Middle Aged; P | 2010 |
[Long-term effect of 3-week intravenous alpha-lipoic acid administration in symptomatic diabetic polyneutropathy with clinical manifestations].
Topics: Antioxidants; Diabetic Neuropathies; Double-Blind Method; Drug Administration Schedule; Female; Foll | 2010 |
Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.
Topics: Adolescent; Adult; Antioxidants; Diabetic Neuropathies; Female; Humans; Male; Middle Aged; Thioctic | 2011 |
Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.
Topics: Adolescent; Adult; Antioxidants; Diabetic Neuropathies; Female; Humans; Male; Middle Aged; Thioctic | 2011 |
Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.
Topics: Adolescent; Adult; Antioxidants; Diabetic Neuropathies; Female; Humans; Male; Middle Aged; Thioctic | 2011 |
Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.
Topics: Adolescent; Adult; Antioxidants; Diabetic Neuropathies; Female; Humans; Male; Middle Aged; Thioctic | 2011 |
Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.
Topics: Adolescent; Adult; Antioxidants; Diabetic Neuropathies; Female; Humans; Male; Middle Aged; Thioctic | 2011 |
Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.
Topics: Adolescent; Adult; Antioxidants; Diabetic Neuropathies; Female; Humans; Male; Middle Aged; Thioctic | 2011 |
Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.
Topics: Adolescent; Adult; Antioxidants; Diabetic Neuropathies; Female; Humans; Male; Middle Aged; Thioctic | 2011 |
Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.
Topics: Adolescent; Adult; Antioxidants; Diabetic Neuropathies; Female; Humans; Male; Middle Aged; Thioctic | 2011 |
Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.
Topics: Adolescent; Adult; Antioxidants; Diabetic Neuropathies; Female; Humans; Male; Middle Aged; Thioctic | 2011 |
The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial.
Topics: Aged; Antioxidants; Diabetic Neuropathies; Female; Humans; Injections, Intravenous; Male; Middle Age | 2003 |
The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial.
Topics: Aged; Antioxidants; Diabetic Neuropathies; Female; Humans; Injections, Intravenous; Male; Middle Age | 2003 |
The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial.
Topics: Aged; Antioxidants; Diabetic Neuropathies; Female; Humans; Injections, Intravenous; Male; Middle Age | 2003 |
The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial.
Topics: Aged; Antioxidants; Diabetic Neuropathies; Female; Humans; Injections, Intravenous; Male; Middle Age | 2003 |
Alpha-lipoic acid in the treatment of autonomic diabetic neuropathy (controlled, randomized, open-label study).
Topics: Adult; Antioxidants; Autonomic Nervous System Diseases; Blood Pressure; Diabetes Mellitus, Type 1; D | 2004 |
[Neurometabolic therapy of diabetic neuropathy].
Topics: Adjuvants, Immunologic; Analgesics, Non-Narcotic; Antioxidants; Blood Glucose; Carbamazepine; Diabet | 2006 |
Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.
Topics: Administration, Oral; Aged; Diabetic Neuropathies; Female; Foot; Humans; Male; Middle Aged; Pain; Pa | 2006 |
Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.
Topics: Administration, Oral; Aged; Diabetic Neuropathies; Female; Foot; Humans; Male; Middle Aged; Pain; Pa | 2006 |
Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.
Topics: Administration, Oral; Aged; Diabetic Neuropathies; Female; Foot; Humans; Male; Middle Aged; Pain; Pa | 2006 |
Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.
Topics: Administration, Oral; Aged; Diabetic Neuropathies; Female; Foot; Humans; Male; Middle Aged; Pain; Pa | 2006 |
An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain.
Topics: Acetaminophen; Amitriptyline; Analgesics; Carbamazepine; Diabetes Complications; Diabetic Neuropathi | 2007 |
Efficacy of thioctic acid in the therapy of peripheral diabetic neuropathy.
Topics: Administration, Oral; Clinical Trials as Topic; Diabetic Neuropathies; Double-Blind Method; Humans; | 1980 |
[Diabetes mellitus--a free radical-associated disease. Results of adjuvant antioxidant supplementation].
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropat | 1993 |
Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study).
Topics: Adolescent; Adult; Aged; Antioxidants; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Neuropath | 1995 |
Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study).
Topics: Adolescent; Adult; Aged; Antioxidants; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Neuropath | 1995 |
Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study).
Topics: Adolescent; Adult; Aged; Antioxidants; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Neuropath | 1995 |
Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study).
Topics: Adolescent; Adult; Aged; Antioxidants; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Neuropath | 1995 |
Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie.
Topics: Autonomic Nervous System Diseases; Blood Pressure; Body Weight; Confounding Factors, Epidemiologic; | 1997 |
Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy.
Topics: Antioxidants; Diabetic Neuropathies; Diet Therapy; Forecasting; Humans; Oxidation-Reduction; Thiocti | 1997 |
[The efficacy of the intravenous administration of the trometamol salt of thioctic (alpha-lipoic) acid in diabetic neuropathy].
Topics: Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Human | 1999 |
Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy.
Topics: Administration, Oral; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind M | 1999 |
Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy.
Topics: Administration, Oral; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind M | 1999 |
Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy.
Topics: Administration, Oral; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind M | 1999 |
Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy.
Topics: Administration, Oral; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind M | 1999 |
Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy.
Topics: Action Potentials; Adolescent; Adult; Aged; Antioxidants; Diabetes Mellitus, Type 1; Diabetes Mellit | 1999 |
Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy.
Topics: Action Potentials; Adolescent; Adult; Aged; Antioxidants; Diabetes Mellitus, Type 1; Diabetes Mellit | 1999 |
Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy.
Topics: Action Potentials; Adolescent; Adult; Aged; Antioxidants; Diabetes Mellitus, Type 1; Diabetes Mellit | 1999 |
Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy.
Topics: Action Potentials; Adolescent; Adult; Aged; Antioxidants; Diabetes Mellitus, Type 1; Diabetes Mellit | 1999 |
Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy.
Topics: Action Potentials; Adolescent; Adult; Aged; Antioxidants; Diabetes Mellitus, Type 1; Diabetes Mellit | 1999 |
Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy.
Topics: Action Potentials; Adolescent; Adult; Aged; Antioxidants; Diabetes Mellitus, Type 1; Diabetes Mellit | 1999 |
Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy.
Topics: Action Potentials; Adolescent; Adult; Aged; Antioxidants; Diabetes Mellitus, Type 1; Diabetes Mellit | 1999 |
Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy.
Topics: Action Potentials; Adolescent; Adult; Aged; Antioxidants; Diabetes Mellitus, Type 1; Diabetes Mellit | 1999 |
Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy.
Topics: Action Potentials; Adolescent; Adult; Aged; Antioxidants; Diabetes Mellitus, Type 1; Diabetes Mellit | 1999 |
Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathy.
Topics: Antioxidants; Blood Flow Velocity; Capillaries; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2000 |
The function of endogenous protective systems in patients with insulin-dependent diabetes mellitus and polyneuropathy: effect of antioxidant therapy.
Topics: Adolescent; Adult; Antioxidants; Diabetes Mellitus, Type 1; Diabetic Neuropathies; Female; Heat-Shoc | 2000 |
80 other studies available for thioctic acid and Diabetic Neuropathies
| Article | Year |
|---|---|
[Diabetic encephalopathy: current insights and potential therapeutic strategies].
Topics: Antioxidants; Brain Diseases; Diabetes Mellitus; Diabetic Neuropathies; Humans; Polyneuropathies; Th | 2021 |
Diurnal efficacy of alpha-lipoic acid/nifedipine/glimepiride combination mitigates diabetic neuropathies in rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Nifedipine; Rats; Sul | 2022 |
Exploring the effectiveness of vitamin B
Topics: Diabetes Mellitus; Diabetic Neuropathies; Humans; Inflammation; Meta-Analysis as Topic; Randomized C | 2022 |
Alpha-lipoic acid activates AMPK to protect against oxidative stress and apoptosis in rats with diabetic peripheral neuropathy.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Diabetes Mellitus; Diabetic Neuropathies; NF-E2-R | 2023 |
Morbidity and mortality of patients with diabetic neuropathy treated with pathogenetically oriented alpha-lipoic acid versus symptomatic pharmacotherapies - A nationwide database analysis from Hungary.
Topics: Antioxidants; Diabetes Mellitus; Diabetic Neuropathies; Humans; Hungary; Retrospective Studies; Thio | 2023 |
To Study the Eff ect of Alpha Lipoic Acid Supplementation on Diabetic Neuropathy through Nerve Conduction Test.
Topics: Antioxidants; Diabetes Mellitus; Diabetic Neuropathies; Dietary Supplements; Humans; Neural Conducti | 2020 |
Metformin Preserves Peripheral Nerve Damage with Comparable Effects to Alpha Lipoic Acid in Streptozotocin/High-Fat Diet Induced Diabetic Rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-Fat; Male; Metformin; Ra | 2020 |
NGF receptors and PI3K/AKT pathway involved in glucose fluctuation-induced damage to neurons and α-lipoic acid treatment.
Topics: Animals; Apoptosis; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Nerve Tissue Pr | 2020 |
The clinical effectiveness and safety of alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropathy: A protocol for systematic review and meta-analysis.
Topics: Alprostadil; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Drug Therapy, Combinati | 2020 |
Effects of alpha-lipoic acid treatment on serum progranulin levels and inflammatory markers in diabetic neuropathy.
Topics: Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; Progranulins; Prospective Studies; Thiocti | 2021 |
Impaired Corneal Sensation and Nerve Loss in a Type 2 Rat Model of Chronic Diabetes Is Reversible With Combination Therapy of Menhaden Oil, α-Lipoic Acid, and Enalapril.
Topics: Adiponectin; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Cornea; Diabetes Mell | 2017 |
The clinical efficacy of epalrestat combined with α-lipoic acid in diabetic peripheral neuropathy: Protocol for a systematic review and meta-analysis.
Topics: Antioxidants; Diabetic Neuropathies; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Meta-Anal | 2018 |
Comparison of peripheral nerve protection between insulin-based glucose control and alpha lipoic acid (ALA) in the streptozotocin (STZ)-induced diabetic rat.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Hypoglycemic Agents; | 2018 |
R(+)-Thioctic Acid Effects on Oxidative Stress and Peripheral Neuropathy in Type II Diabetic Patients: Preliminary Results by Electron Paramagnetic Resonance and Electroneurography.
Topics: Aged; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Electric Stimulation; Electron | 2018 |
Effects of Alpha Lipoic Acid on Loss of Myelin Sheath of Sciatic Nerve in Experimentally Induced Diabetic Rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Models, Anima | 2018 |
Alpha-lipoic acid and coenzyme Q10 combination ameliorates experimental diabetic neuropathy by modulating oxidative stress and apoptosis.
Topics: Administration, Oral; Animals; Apoptosis; Biomarkers; Blotting, Western; Caspase 3; Diabetes Mellitu | 2019 |
Biomarkers of response to alpha-lipoic acid ± palmitoiletanolamide treatment in patients with diabetes and symptoms of peripheral neuropathy.
Topics: Adult; Aged; Amides; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Diabetic Neuropathies; Ethanola | 2019 |
[Efficacy of thiolepta in diabetic polyneuropathy: results of the study ETIKA].
Topics: Antioxidants; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropat | 2013 |
[The effect of long-chain polyunsaturated higher ω-3 fatty acids, benfotiamine and α-lipoic acid on the lipid metabolism in patients with diabetes mellitus type 2 and cardiovascular autonomic neuropathy].
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; D | 2013 |
The neuroprotective benefit from pioglitazone (PIO) addition on the alpha lipoic acid (ALA)-based treatment in experimental diabetic rats.
Topics: Animals; Axons; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Drug Therapy, | 2014 |
Comment on Xu et al.: Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy.
Topics: Diabetic Neuropathies; Humans; Peripheral Nervous System Diseases; Thioctic Acid; Vitamin B 12 | 2014 |
Comment on Xu et al.: Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy.
Topics: Diabetic Neuropathies; Humans; Peripheral Nervous System Diseases; Thioctic Acid; Vitamin B 12 | 2014 |
Combination therapies prevent the neuropathic, proinflammatory characteristics of bone marrow in streptozotocin-induced diabetic rats.
Topics: Adipose Tissue; Animals; Bone Marrow; Cytokines; Diabetes Mellitus, Experimental; Diabetic Neuropath | 2015 |
Alpha-lipoic acid modifies circulating angiogenic factors in patients with type 2 diabetes mellitus.
Topics: Aged; Angiogenesis Inducing Agents; Case-Control Studies; Chemokine CCL2; Comorbidity; Coronary Arte | 2015 |
Effect of combination therapy consisting of enalapril, α-lipoic acid, and menhaden oil on diabetic neuropathy in a high fat/low dose streptozotocin treated rat.
Topics: Animals; Cornea; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Neuropathies; | 2015 |
Alpha-Lipoic Acid for Treatment of Diabetic Peripheral Neuropathy.
Topics: Administration, Intravenous; Antioxidants; Diabetic Neuropathies; Humans; Thioctic Acid | 2016 |
[Clinical aspects of pharmacological treatment of diabetic neuropathy - cooperation with neurologists and diabetologists].
Topics: Analgesics, Opioid; Anticonvulsants; Antidepressive Agents; Antioxidants; Cooperative Behavior; Diab | 2016 |
Evaluation of Electrophysiological Effects of Melatonin and Alpha Lipoic Acid in Rats with Streptozotocine Induced Diabetic Neuropathy.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Diabetic Neuropathies; Disease Models, Animal; E | 2016 |
Early vs. late intervention of high fat/low dose streptozotocin treated C57Bl/6J mice with enalapril, α-lipoic acid, menhaden oil or their combination: Effect on diabetic neuropathy related endpoints.
Topics: Acute Disease; Animals; Chronic Disease; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dru | 2017 |
Coenzyme Q(10) and alpha-lipoic acid supplementation in diabetic rats: conduction velocity distributions.
Topics: Action Potentials; Animals; Antioxidants; Blood Glucose; Body Weight; Diabetes Mellitus, Experimenta | 2008 |
[The use of dipyridamole (curantyl) in combination with alpha-lipoic acid in the treatment of diabetic neuropathy with retinopathy].
Topics: Adult; Aged; Antioxidants; Diabetic Neuropathies; Diabetic Retinopathy; Dipyridamole; Drug Therapy, | 2008 |
The role of alpha-lipoic acid in diabetic polyneuropathy treatment.
Topics: Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Hu | 2008 |
Nonparametric non-inferiority analyses in the three-arm design with active control and placebo.
Topics: Clinical Trials as Topic; Computer Simulation; Diabetic Neuropathies; Humans; Multicenter Studies as | 2009 |
[Treatment of neuropathies].
Topics: Adjuvants, Immunologic; Adrenergic Uptake Inhibitors; Amines; Analgesics; Antioxidants; Capsaicin; C | 2010 |
Neuropathy in a rat model of mild diabetes induced by multiple low doses of streptozotocin: effects of the antioxidant stobadine in comparison with a high-dose alpha-lipoic acid treatment.
Topics: Animals; Antioxidants; Carbolines; Diabetic Neuropathies; Disease Models, Animal; Humans; Male; Neur | 2010 |
Managing diabetic peripheral neuropathic pain in primary care.
Topics: Acetylcarnitine; Analgesics; Antidepressive Agents; Diabetic Neuropathies; Drug Therapy, Combination | 2010 |
[Atrial fibrillation in patients with type 2 diabetes mellitus: specific features of development and antirecurrence therapy].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Atrial Fi | 2010 |
Thioctic acid-induced acute cholestatic hepatitis.
Topics: Antioxidants; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Diabetes Mellitus, | 2011 |
α-Lipoic acid, diabetic neuropathy, and Nathan's prophecy.
Topics: Clinical Trials as Topic; Diabetic Neuropathies; Humans; Thioctic Acid; Treatment Outcome | 2012 |
[Antihypoxic effect of 3-hydroxypyridine and succinic acid derivatives and their nootropic action in alloxan diabetes].
Topics: Alloxan; Animals; Conditioning, Classical; Diabetes Mellitus, Experimental; Diabetic Neuropathies; D | 2011 |
[The clinic, diagnosis, complex treatment of diabetic polyneuropathy].
Topics: Acupuncture; Acupuncture Points; Combined Modality Therapy; Diabetic Neuropathies; Drug Therapy, Com | 2012 |
The effectiveness of treatments of diabetic autonomic neuropathy is not the same in autonomic nerves supplying different organs.
Topics: Animals; Antioxidants; Autonomic Nervous System Diseases; Autonomic Pathways; Calcitonin Gene-Relate | 2003 |
[Polyneuropathy--therapy].
Topics: Antioxidants; Diabetic Neuropathies; Humans; Thioctic Acid | 2003 |
Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation.
Topics: Animals; Arginine; Arterioles; Cyclic N-Oxides; Diabetes Mellitus, Experimental; Diabetic Neuropathi | 2003 |
Acute glucose deprivation leads to apoptosis in a cell model of acute diabetic neuropathy.
Topics: Animals; Antioxidants; Apoptosis; Benzamides; Caspase 3; Caspases; Cell Count; Cell Hypoxia; Cell Su | 2003 |
[On the treatment of diabetic neuropathy].
Topics: Diabetes Mellitus; Diabetic Neuropathies; Humans; Neurologic Manifestations; Thioctic Acid | 1961 |
[Treatment of polyneuritic complications in diabetes with thioctic acid].
Topics: Diabetes Mellitus; Diabetic Neuropathies; Humans; Neuritis; Thioctic Acid | 1963 |
[DIABETIC NEUROPATHIES AND THEIR TREATMENT].
Topics: Diabetic Neuropathies; Diagnosis; Liver Extracts; Pantothenic Acid; Pathology; Physiology; Procaine; | 1964 |
Potent antioxidant improves diabetic nerve damage.
Topics: Antioxidants; Diabetic Neuropathies; Female; Humans; Thioctic Acid | 2003 |
Prevention and partial reversal of diabetes-induced changes in enteric nerves of the rat ileum by combined treatment with alpha-lipoic acid and evening primrose oil.
Topics: Animals; Calcitonin Gene-Related Peptide; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dr | 2004 |
Neuroprotection by alpha-lipoic acid in streptozotocin-induced diabetes.
Topics: Animals; Antioxidants; Biomarkers; Brain Chemistry; Diabetes Mellitus, Experimental; Diabetic Neurop | 2004 |
Diabetic neuropathy--choices of treatment.
Topics: Adult; Antioxidants; Diabetic Neuropathies; Female; Humans; Infusions, Intravenous; Male; Middle Age | 2002 |
[Evidence-based management of diabetic polyneuropathy. "Burning feet" alarm signal].
Topics: Amines; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Diabetic Foot; Diabetic Neuropathies | 2004 |
Treatment for diabetic mononeuropathy with alpha-lipoic acid.
Topics: Administration, Oral; Adult; Aged; Antioxidants; Cranial Nerve Diseases; Diabetic Neuropathies; Fema | 2005 |
[Predictors of alpha-lipoic acid treatment efficacy in diabetic polyneuropathy of the lower limbs].
Topics: Adult; Antioxidants; Diabetes Mellitus, Type 1; Diabetic Neuropathies; Electrophysiology; Female; Hu | 2005 |
At low doses, a gamma-linolenic acid-lipoic acid conjugate is more effective than docosahexaenoic acid-enriched phospholipids in preventing neuropathy in diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Docosahexaenoic Acids; Dose-Respons | 2007 |
The effect of alpha-lipoic acid on symptoms and skin blood flow in diabetic neuropathy.
Topics: Antioxidants; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Humans; Injections, Intraven | 2007 |
[Therapeutic possibilities in polyneuropathies].
Topics: Adult; Aged; Diabetic Neuropathies; Humans; Methionine; Middle Aged; Nervous System Diseases; Neurit | 1982 |
[Diabetic autonomic neuropathy of the heart and its treatment with thioctic acid].
Topics: Aged; Autonomic Nervous System Diseases; Diabetic Neuropathies; Female; Heart; Heart Rate; Humans; M | 1984 |
Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Ganglia, Spinal; Glutathione; Human | 1995 |
Thioctic (lipoic) acid: a therapeutic metal-chelating antioxidant?
Topics: Antioxidants; Ascorbic Acid; Chelating Agents; Copper; Diabetic Neuropathies; Erythrocytes; Humans; | 1995 |
Alpha-lipoic acid: antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy.
Topics: Animals; Antioxidants; Brain; Diabetic Neuropathies; Dose-Response Relationship, Drug; Free Radicals | 1996 |
alpha-Lipoic acid in NIDDM patients with cardiac autonomic neuropathy.
Topics: Autonomic Nervous System Diseases; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; Researc | 1997 |
[Alpha-lipoic acid in diabetic neuropathy. Action mechanism and therapy. Clinical picture and pathogenesis of diabetic neuropathy].
Topics: Diabetic Neuropathies; Humans; Thioctic Acid | 1994 |
Effects of alpha-lipoic acid on neurovascular function in diabetic rats: interaction with essential fatty acids.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; gamma-L | 1998 |
A lipoic acid-gamma linolenic acid conjugate is effective against multiple indices of experimental diabetic neuropathy.
Topics: Animals; Antioxidants; Butylated Hydroxytoluene; Diabetes Mellitus, Experimental; Diabetic Neuropath | 1998 |
Insufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes.
Topics: Adult; Antioxidants; Biomarkers; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 1; | 1998 |
Effects of diabetes and treatment with the antioxidant alpha-lipoic acid on endothelial and neurogenic responses of corpus cavernosum in rats.
Topics: Acetylcholine; Animals; Antioxidants; Atropine; Blood Glucose; Body Weight; Diabetes Mellitus, Exper | 1999 |
The effect of alpha-lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy.
Topics: Adult; Aged; Antioxidants; Blood Flow Velocity; Body Mass Index; Cold Temperature; Diabetic Neuropat | 1999 |
[Drug prescriptions and costs in diabetic polyneuropathy].
Topics: Aged; Aged, 80 and over; Analgesics; Antidepressive Agents; Diabetic Neuropathies; Drug Costs; Femal | 1999 |
Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dose-Response Relati | 1999 |
Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy.
Topics: Animals; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Energy Metabolism; Enz | 2000 |
[Diabetic polyneuropathy. Sequential therapy with alpha-lipoic acid passes the general practice test].
Topics: Adult; Antioxidants; Diabetic Neuropathies; Humans; Thioctic Acid; Treatment Outcome | 2000 |
[Diabetic neuropathy].
Topics: Acupuncture Therapy; Adjuvants, Immunologic; Antioxidants; Combined Modality Therapy; Diabetic Neuro | 2000 |
Oxidative stress participates in the breakdown of neuronal phenotype in experimental diabetic neuropathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; gamma-Linolenic Acid; Male; Nerve G | 2001 |
Glutathione and alpha-lipoate in diabetic rats: nerve function, blood flow and oxidative state.
Topics: Animals; Antioxidants; Blood Flow Velocity; Diabetes Mellitus, Experimental; Diabetic Neuropathies; | 2001 |
[Treatment of diabetic neuropathy with oral alpha-lipoic acid (author's transl)].
Topics: Administration, Oral; Adult; Aged; Diabetic Neuropathies; Female; Humans; Injections, Intravenous; M | 1975 |
[Drug treatment of diabetic polyneuropathy with alpha-lipoic acid or vitamin B preparations. A clinical and neurophysiologic study].
Topics: Adult; Diabetic Neuropathies; Female; Humans; Median Nerve; Middle Aged; Reaction Time; Refractory P | 1988 |
[Diabetic neuropathy].
Topics: Aged; Diabetes Mellitus; Diabetic Neuropathies; Humans; Middle Aged; Thiamine; Thioctic Acid | 1969 |
[What is reliable in the therapy of diabetes mellitus?].
Topics: Carbutamide; Chlorpropamide; Chronic Disease; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nep | 1970 |